NCT06801795已完成不适用
Evaluation of a 1726nm Laser for the Treatment of Hidradenitis Suppurativa (HS)
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 8
- 试验地点
- 1
- 主要终点
- Change in HiSCR50 as measured by percentage of participants
研究概览
简要总结
The objective is to evaluate the safety and efficacy of the Cutera 1726 nm laser system (also referred to as AviClear) for the treatment of HS.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Female or Male.
- •Fitzpatrick Skin Types I-VI.
- •18 to 60 years of age.
- •Has a clinical diagnosis of HS (stage 1-2 on the Hurley scale [Appendix 1] based on assessment by the investigator).
- •Presence of nodule(s) in the bilateral axillas, inguinal, infra-mammary, thighs, or buttocks within the past 4 weeks
- •Subject must be able to read, speak, and understand English or Spanish and sign the Informed Consent Form.
- •Willing and able to adhere to the treatment and follow-up schedule and pre/post-treatment care instructions.
- •No contraindication to laser therapy.
- •Willing to undergo biopsy at the beginning of study and end of study.
- •Willing to have photographs taken of the treatment area and agree to the use of photographs for presentation, educational or marketing purposes.
- •Agree to not undergo any other procedure(s) or add any new treatment modalities in the treatment area during the study.
- •Willing to use investigator approved skincare topicals and follow investigator approved skincare regimen for the duration of the study.
排除标准
- •Has clinically diagnosed HS of severity grade 3 based on assessment by the investigator.
- •Absence of nodule(s) in the bilateral axilla, inguinal, infra-mammary, thighs, or buttocks within the past 4 weeks.
- •Prior treatment to the target area during participation in a clinical trial of another device or drug within 1 month (30 days) prior to study participation.
- •Prior treatment to the target area within 3 months of study participation including chemical peel, dermabrasion, microneedling, radiofrequency treatment, laser or light-based procedures, cryodestruction or chemodestruction, intralesional steroids, photodynamic therapy, or acne surgery.
- •Prior injection of botulinum toxin in the target area within 3 months of study participation and for the duration of the study.
- •Systemic use of retinoid, such as isotretinoin, within 3 months of study participation.
- •Still healing from another treatment in the target area according to investigator's discretion.
- •History of malignant tumors in the target area.
- •Excessive hair that may preclude treatments, photos or accurate HS assessments in the target area (okay if shaved).
- •Pregnant and/or breastfeeding or planning to become pregnant during the study.
- •Suffering from diagnosed coagulation disorders or taking prescription anticoagulation medications.
- •History of diagnosed immunosuppression/immune deficiency disorders or currently using immunosuppressive medications.
- •History of diagnosed connective tissue disease, such as systemic lupus erythematosus or scleroderma.
- •Any use of medication that is known to increase sensitivity to light according to Investigator's discretion.
- •History of disease stimulated by heat, such as recurrent herpes simplex and/or herpes zoster (shingles) in the target area, unless treatment is conducted following a prophylactic regimen.
- •History of radiation to the target area, currently undergoing treatment for skin cancer in the target area or undergoing systemic chemotherapy for the treatment of cancer.
- •History of diagnosed pigmentary disorders (including vitiligo) in the target area.
- •Excessively tanned in the treatment area or unable/unlikely to refrain from tanning in the target area during the study.
- •History of keloids or hypertrophic scarring
- •As per the Investigator's discretion, any physical, mental or medical condition which might make it unsafe for the subject to participate in this study, might interfere with patient's participation in the full study protocol, or might interfere with the diagnosis or assessment of HS.
研究组 & 干预措施
AviClear Group
Experimental
Participants will be in this group for up to 43 weeks.
干预措施: AviClear (Device)
结局指标
主要结局
Change in HiSCR50 as measured by percentage of participants
时间窗: Baseline, up to 24 weeks (after final treatment)
Percentage of participants achieving Hidradenitis Suppurativa Clinical Response 50 (HiSCR50, where HiSCR50 is defined as at least a 50% reduction from baseline in abscess and inflammatory nodule (AN) count, with no increase from baseline in abscess or draining fistula count.
次要结局
- Change in pain as measured by Visual Analogue Scale Pain Rating Scale(Baseline, up to 24 weeks (after final treatment))
- Change in number of lesions(Baseline, up to 24 weeks (after final treatment))
- Change in IHS 4(Baseline, up to 24 weeks (after final treatment))
- Change in number of Patient's stage category as measured by Hurley Stage(Baseline, up to 24 weeks (after final treatment))
研究者
Ariel Eva Eber
Assistant Professor of Clinical
University of Miami
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A Device Study for the Treatment of AcneAcne VulgarisNCT04695691Cutera Inc.104
已完成
不适用
A Clinical Evaluation of a Novel Multi-Wavelength Laser for Benign Pigmented Lesion RemovalPigmented Skin Lesion of Suspected Benign NatureNCT02635880Cutera Inc.32
已完成
不适用
A Single-Center Open-Label Study of 1064 nm for Nonablative Skin RejuvenationSkin PigmentPhotoagingNCT03421691Cutera Inc.17
已完成
4 期
Presbyopic Supracor Treatment for Near Myopic/Hyperopic Pseudophakic EyesMyopiaPresbyopiaHyperopiaNCT01387360Technolas Perfect Vision GmbH33
已完成
不适用
Clinical Investigation to Assess the Safety and Efficacy of the Laser for the Treatment of Vulvovaginal AtrophyVulvovaginal AtrophyNCT02085980El. En. SpA30